MAPPING GENES FOR SCHIZOPHRENIA IN FOUNDER POPULATIONS

描述（改编自研究者摘要）：长期目的 这项提议的一个重要方面是鉴定导致精神分裂症的基因 易感性研究人员建议首先确定基因组区域， 通过在遗传学上进行连锁研究， 孤立的种群（起源于少数 创始人并在相对孤立的情况下扩张）。 为此，调查人员收集了患有 精神分裂症的遗传隔离的创始人人群， 不同的人口统计学特征（样本大小，增长 在他们的祖先时代也是如此。具体来说，他们收集了 来自密克罗尼西亚的科斯雷和雅普岛种群的家族（遗传 最近起源的分离株）和南非的阿非利卡人（遗传分离株 “老”的起源）。这三个网站都提供了极好的家谱数据， 可以显著提高评估证据的能力， 等位基因或区段共享受影响的个人之间，考虑到所有 已知的家谱关系。研究人员建议进行一个10厘米的 在他们收集的家庭中进行全基因组扫描， 通过10-cM扫描通过更密集的标记覆盖识别区域， 单倍型的构建。 对增加精神分裂症易感性的基因的鉴定是 有望对疾病发病机制的认识产生重大影响 并最终导致新的、较少经验的疗法的发展。

DESCRIPTION (Adapted from the Investigator's Abstract): The long-term objective of this proposal is the identification of genes contributing to schizophrenia susceptibility. The investigators propose to first identify the genomic regions which may harbor such genes by performing linkage studies in genetically isolated populations (populations that originated from a small number of founders and expanded in relative isolation). To this end, the investigators have collected families afflicted with schizophrenia from genetically isolated founder populations with accessible genealogy that differ in their demographic characteristics (sample size, growth rate) as well in their age of ancestry. Specifically, they have collected families from the island populations of Kosrae and Yap in Micronesia (genetic isolates of recent origin), and the Afrikaners in South Africa (genetic isolate of 'older' origin). All three sites offer excellent genealogical data that could significantly improve the ability to assess the evidence for increased allele or segment sharing among affected individuals by taking into account all known genealogical relationships. The investigators propose to perform a 10-cM genome-wide scan in the families they have collected and examine all 'candidate regions' identified through the 10-cM scan by denser marker coverage and construction of haplotypes. The identification of genes that increase susceptibility to schizophrenia is expected to have a major impact on the understanding of disease pathogenesis and, ultimately, lead to the development of new, less empirical therapies.